Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group
Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in
breast cancer, has limited value for treatment decisions due to questionable analytical …
breast cancer, has limited value for treatment decisions due to questionable analytical …
[HTML][HTML] Triple‑negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International journal of …, 2020 - … .spandidos-publications.com
Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
[HTML][HTML] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Highlights•This ESO-ESMO ABC 5 Clinical Practice Guideline provides key
recommendations for managing advanced breast cancer patients.•It provides updates on …
recommendations for managing advanced breast cancer patients.•It provides updates on …
Breast cancer treatment
KP Trayes, SEH Cokenakes - American family physician, 2021 - aafp.org
Breast cancer is the leading cause of death from cancer in women worldwide, and the
second most common cause of death from cancer in women in the United States. Risk …
second most common cause of death from cancer in women in the United States. Risk …
[HTML][HTML] Evolution of low HER2 expression between early and advanced-stage breast cancer
Background Low human epidermal growth factor receptor 2 (HER2) expression is emerging
as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 …
as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 …
Therapeutic resistance to anti-oestrogen therapy in breast cancer
The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …
gland development, breast carcinogenesis and the progression of breast tumours into lethal …
HER2-low breast cancer: molecular characteristics and prognosis
Simple Summary The dichotomous classification of HER2 status is experiencing a paradigm
change, leading to the identification of the so-called “HER2-low” category. The aim of our …
change, leading to the identification of the so-called “HER2-low” category. The aim of our …
Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor–positive …
K Kalinsky, MK Accordino, C Chiuzan… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET)
improves progression-free survival (PFS) and overall survival (OS) in hormone receptor …
improves progression-free survival (PFS) and overall survival (OS) in hormone receptor …
Systemic therapy for estrogen receptor–positive, HER2-negative breast cancer
HJ Burstein - New England Journal of Medicine, 2020 - Mass Medical Soc
Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …
CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and …
PURPOSE CALGB 40603 (NCT00861705), a 2× 2 randomized phase II trial, demonstrated
that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin …
that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin …